Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

TOP PICK

Their major drug in oncology treats cancer and will earn $18 billion in revenue this year. Trades at 12x earnings and pays a large dividend. MRK has a strong balance sheet, their drug pipeline promises future growth, their balance sheet is strong, and they can resist hot inflation. (Analysts’ price target is $96.34)

BUY

options There's been a huge spike in options in healthcare stocks. Merck started seeing options activity in late March. Today sees 14,000 of the May $87.50 calls for $1.50.

BUY

Some growth, especially in its blockbuster drug, which makes up 1/3 of total revenue. An uncomfortable concentration, but the patents are long-dated. Good dividend, AAA balance sheet, reasonable multiple at 11x.

BUY

He's long this. You're finally getting a technical breakout. The stock is at the highest levels of the year. Take advantage of the valuation discount for the healthcare sector compared to the S&P.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O’Reilly With several developmental cancer drugs continuing to make good progress, we again reiterate this $195 billion marketcap global drug manufacturer as a TOP PICK. Recently reported earnings beat expectations by over 20% and the company is managing a ROE over 45%. Trading at 16x forward earnings, compared with its peers at 21x, it is good value here. It pays a good dividend, backed by payout ratio under 55% of cash flow. We recommend trailing up the stop (from $70) to $74, looking to achieve $92.50 -- upside potential of 15%. Yield 3.4% (Analysts’ price target is $92.38)

BUY

It trades at 12x earnings with a solid growth rate, based on their major oncology drug. Also, their drug pipeline is solid. Dividend is healthy.

HOLD

Good large cap with reasonable growth. Really likes its diversity. Oncology, diabetes, immunology, globally #2 in animal health. Competition from BMY and LLY. Lacklustre R&D. Happy to hold through the volatility.

PAST TOP PICK

(A Top Pick Jan 10/20, Down 3%) Stock price popped on news of therapeutic pill. We're in a medical emergency, yet drug space is languishing, quite extraordinary. Lots of value. Model price of $146, 90% upside. Yield is 3.4%

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This $195 billion marketcap global drug manufacturer has just received FDA emergency approval for an oral COVID-19 treatment and is reiterated as a TOP PICK. Japan just committed to 200,000 doses of the new pill. Trading at 11x forward earnings, compared with its peers at 19x, it is good value here. It pays an excellent dividend, backed by payout ratio under 50% of forward cash flow. We recommend trailing up the stop (from $65) to $70, looking to achieve $92.50 -- upside potential of 19%. Yield 3.59% (Analysts’ price target is $92.31)

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

The pandemic casued a decline in the use of their drugs in hospitals. This should return eventually. The new anti-covid pill is also a short-term win. Social media mentions are up 467% in the last 24 hours.

TOP PICK

A laggard, as pandemic caused a decline in its drugs used in hospitals. This demand will eventually return. Demand for new anti-Covid pill will be a short-term winner. Decently valued. Yield is 3.23%. (Analysts’ price target is $94.82)

BUY

Today, Merck may have beaten Covid. That's why the market rallied today. Today had nothing to do with inflation or supply shortages. If you take this pill after testing positive for Covid, the pill can save you and crush symptoms. Merck can produce 10 million course of these pills by year's end. No wonder Merck shares surged nearly 9% today. Industrials and delivery stocks could be worth buying now.

BUY

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

WATCH

They have an analyst meeting on Monday. Watch that, because they reported ugly numbers earlier this week.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly MRK returns as a TOP PICK. Trading at 17 times earnings, compared with its peers at 40x it is good value here. It pays an excellent dividend, backed by payout ratio of only 50% of cash flow. We would buy it here with a stop-loss at $65, looking to achieve $96 -- upside potential of 23%. Yield 3.36% (Analysts’ price target is $96.33)

Showing 91 to 105 of 304 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)